About Us

Overview

EpiCept is a specialty pharmaceutical company that focuses on fulfilling unmet medical needs in cancer treatment and pain management. The Company possesses a cancer product, Ceplene®, approved in the European Union and a deep and balanced pipeline of three major clinical product candidates, including:

• AmiKet™ (formerly known as EpiCept™ NP-1), a pain medication that has completed Phase II clinical trials.
• Crolibulin™, an apoptosis inducer for solid vascularized tumors that is currently in Phase I clinical trials.
• Azixa™, an oncology compound that is currently in Phase II trials for brain cancer.

EpiCept is headquartered in Tarrytown, New York, and also possesses a subsidiary in Munich, Germany, that is responsible for pharmacovigilance of Ceplene®.

EpiCept is listed on both the NASDAQ Capital Market and the Nasdaq OMX Stockholm Exchange, under the symbol “EPCT”.

Vision and Mission

EpiCept’s vision is to create and develop products that make a meaningful difference in people’s lives. As such, it is dedicated to successfully increasing the life span of cancer patients and continually improving the quality of life of pain sufferers.

Our mission is the relentless pursuit of satisfying unmet medical needs with pharmacologic agents that are based on sound scientific findings, demonstrated safety and efficacy, and unique and proven technologies. We are focused on advancing a pipeline of world-class products that treat malignant diseases and moderate-to-severe pain.

EpiCept is focused on the development and commercialization of pharmaceutical products for the treatment of cancer and pain. The Company's lead product is Ceplene®, which has been granted full marketing authorization by the European Commission for the remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia in first remission. The Company has two oncology drug candidates currently in clinical development that were discovered using in-house technology and have been shown to act as vascular disruption agents in a variety of solid tumors.

In the area of pain, EpiCept’s product candidates are designed to topically deliver FDA-approved pain management therapeutics directly to the surface of the skin, which the Company believes will offer patients a safer, more beneficial form of pain relief than traditional systemic forms of analgesics. Because these product candidates utilize FDA-approved drug substances, EpiCept believes that there will be a more streamlined regulatory approval pathway for these product candidates, reducing development risk and costs and potentially accelerating the time to market. The Company's pain portfolio includes AmiKet™, a prescription topical analgesic cream in late-stage clinical development designed to provide effective long-term relief of pain associated with peripheral neuropathies.

EpiCept seeks to generate significant value for its shareholders by developing effective drug candidates, including new chemical entities and new uses for existing therapies, advancing them into late-stage clinical development and then seeking marketing approval either alone or in conjunction with strategic partners.

Business Model

EpiCept possesses a unique business model that sets it apart from typical specialty pharmaceutical and biotech companies and presents a unique value proposition to investors.

In developing analgesic product candidates, EpiCept utilizes several proprietary formulations and topical delivery technologies to administer FDA-approved analgesics to patients. The utilization of these FDA-approved drugs is expected to reduce the risks associated with new drug development, lower development costs and speed time to market for product candidates.

EpiCept plans to market products for which it obtains regulatory approval through its own sales force in the U.S. whenever it is consistent with the market potential of the candidate drug. If the market opportunity requires a larger sales force, the Company will pursue co-marketing, co-promotion, licensing and distribution arrangements with third-party collaborators. The Company retains maximum flexibility to select the marketing method that will optimize market penetration and commercial acceptance of its products.